{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:47Z","timestamp":1792798787638,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Programmed death-ligand 1 (PD-L1) has emerged as an important player in intrinsic tumor cell biology besides its canonical immune checkpoint function. Cumulative experimental data points to a role for PD-L1 in promoting and maintaining an invasive cell phenotype within different cancer cells through its interaction with mechanistic target of rapamycin (mTOR) signaling. In this review, we summarize the main experimental data pointing to the PD-L1\/mTOR interaction in tumor cell invasion capacity both in vitro and in vivo. In this crosstalk, PD-L1 expression is induced by IFN-\u03b3\/STAT1 and IL-6\/STAT3 pathways, as well as mTOR activity by its upstream effectors like EGFR and other tyrosine kinase receptor ligands. Interestingly, PD-L1 itself seems to play a role in mTOR activation. In many of these models, the PD-L1 importance in cell migration capacity is evidenced by two major observations: (1) its knockout impairs cell invasion capacity and, (2) its upregulation is associated with increased cell migration and both the induction and maintenance of epithelial-mesenchymal transition (EMT) phenotype markers, such as increased N-cadherin and ZEB1 and decreased E-cadherin. We also summarize the main clinical trials combining mTOR pathway inhibitors with anti-PD-L1 antibodies in different cancer types.<\/jats:p>","DOI":"10.1007\/s11033-026-12982-6","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:25:21Z","timestamp":1792751121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The PD-L1\u2013mTOR intersection in tumor migration and invasion"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-6174","authenticated-orcid":false,"given":"Rafael","family":"Palavro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5718-339X","authenticated-orcid":false,"given":"Thales Thor Ramos","family":"Previato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2191-7789","authenticated-orcid":false,"given":"Douglas Bottega","family":"Pazzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4188-6316","authenticated-orcid":false,"given":"J\u00falia Budelon","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-9231","authenticated-orcid":false,"given":"Marina Ottmann","family":"Boff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-0745","authenticated-orcid":false,"given":"Daniel","family":"Marinowic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-1515","authenticated-orcid":false,"given":"Jaderson Costa","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-568X","authenticated-orcid":false,"given":"Thamiris Becker","family":"Scheffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"12982_CR1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365\u20131369. https:\/\/doi.org\/10.1038\/70932","journal-title":"Nat Med"},{"key":"12982_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Honjo T (2006) The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27:195\u2013201. https:\/\/doi.org\/10.1016\/j.it.2006.02.001","journal-title":"Trends Immunol"},{"key":"12982_CR3","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1073\/pnas.0712278105","volume":"105","author":"DY-W Lin","year":"2008","unstructured":"Lin DY-W, Tanaka Y, Iwasaki M et al (2008) The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A 105:3011\u20133016. https:\/\/doi.org\/10.1073\/pnas.0712278105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12982_CR4","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak KM, Kitel R, Przetocka S et al (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure 23:2341\u20132348. https:\/\/doi.org\/10.1016\/j.str.2015.09.010","journal-title":"Structure"},{"key":"12982_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"J-H Cha","year":"2019","unstructured":"Cha J-H, Chan L-C, Li C-W et al (2019) Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell 76:359\u2013370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030","journal-title":"Mol Cell"},{"key":"12982_CR6","unstructured":"Scheffel TB, Begnini KR (2025) The Science of PD-1\/PD-L1 Pathway in Gliomas: Far beyond the Obvious | IntechOpen. In: IntechOpen. https:\/\/www.intechopen.com\/chapters\/1220060. Accessed 28 Sept 2026"},{"key":"12982_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"12982_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"12982_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027\u20131034. https:\/\/doi.org\/10.1084\/jem.192.7.1027","journal-title":"J Exp Med"},{"key":"12982_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"12982_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00923.x","journal-title":"Immunol Rev"},{"key":"12982_CR12","doi-asserted-by":"publisher","first-page":"115569","DOI":"10.1016\/j.biopha.2023.115569","volume":"167","author":"P Zhang","year":"2023","unstructured":"Zhang P, Wang Y, Miao Q, Chen Y (2023) The therapeutic potential of PD-1\/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components. Biomed Pharmacother Biomedecine Pharmacother 167:115569. https:\/\/doi.org\/10.1016\/j.biopha.2023.115569","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"12982_CR13","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther 9:5023\u20135039. https:\/\/doi.org\/10.2147\/OTT.S105862","journal-title":"OncoTargets Ther"},{"key":"12982_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A (2015) Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov 5:915\u2013919. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0563","journal-title":"Cancer Discov"},{"key":"12982_CR15","doi-asserted-by":"publisher","first-page":"e1029704","DOI":"10.1080\/2162402X.2015.1029704","volume":"4","author":"S Berry","year":"2015","unstructured":"Berry S, Taube JM (2015) Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. OncoImmunology 4:e1029704. https:\/\/doi.org\/10.1080\/2162402X.2015.1029704","journal-title":"OncoImmunology"},{"key":"12982_CR16","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.3390\/ijms20205138","volume":"20","author":"Y-M Li","year":"2019","unstructured":"Li Y-M, Yu J-M, Liu Z-Y et al (2019) Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8\u2009+\u2009T Cells in Non-Small Cell Lung Cancer. Int J Mol Sci 20:5138. https:\/\/doi.org\/10.3390\/ijms20205138","journal-title":"Int J Mol Sci"},{"key":"12982_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: The Next Generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"12982_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 27:450\u2013461. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"key":"12982_CR19","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T (2020) Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol 13:100773. https:\/\/doi.org\/10.1016\/j.tranon.2020.100773","journal-title":"Transl Oncol"},{"key":"12982_CR20","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/annonc\/mdu452","volume":"25","author":"D Massi","year":"2014","unstructured":"Massi D, Brusa D, Merelli B et al (2014) PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol Off J Eur Soc Med Oncol 25:2433\u20132442. https:\/\/doi.org\/10.1093\/annonc\/mdu452","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"12982_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, Qiu J, O\u2019Sullivan D et al (2015) Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162:1229\u20131241. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016","journal-title":"Cell"},{"key":"12982_CR22","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 375:1767\u20131778. https:\/\/doi.org\/10.1056\/NEJMra1514296","journal-title":"N Engl J Med"},{"key":"12982_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 168:960\u2013976. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"key":"12982_CR24","doi-asserted-by":"publisher","first-page":"10042","DOI":"10.3390\/ijms251810042","volume":"25","author":"J Zhan","year":"2024","unstructured":"Zhan J, Harwood F, Have ST et al (2024) Assembly of mTORC3 Involves Binding of ETV7 to Two Separate Sequences in the mTOR Kinase Domain. Int J Mol Sci 25:10042. https:\/\/doi.org\/10.3390\/ijms251810042","journal-title":"Int J Mol Sci"},{"key":"12982_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","volume":"21","author":"J Kim","year":"2019","unstructured":"Kim J, Guan K-L (2019) mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol 21:63\u201371. https:\/\/doi.org\/10.1038\/s41556-018-0205-1","journal-title":"Nat Cell Biol"},{"key":"12982_CR26","first-page":"1602","volume":"5","author":"P Xia","year":"2015","unstructured":"Xia P, Xu X-Y (2015) PI3K\/Akt\/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res 5:1602\u20131609","journal-title":"Am J Cancer Res"},{"key":"12982_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L et al (2021) Regulation of PD-L1 expression in the tumor microenvironment. J Hematol OncolJ Hematol Oncol 14:10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"12982_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1159\/000460504","volume":"41","author":"J Li","year":"2017","unstructured":"Li J, Chen L, Xiong Y et al (2017) Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 41:907\u2013920. https:\/\/doi.org\/10.1159\/000460504","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"12982_CR29","doi-asserted-by":"publisher","first-page":"111436","DOI":"10.1016\/j.biopha.2021.111436","volume":"138","author":"P Lotfinejad","year":"2021","unstructured":"Lotfinejad P, Kazemi T, Safaei S et al (2021) PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomed Pharmacother Biomedecine Pharmacother 138:111436. https:\/\/doi.org\/10.1016\/j.biopha.2021.111436","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"12982_CR30","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G et al (2016) Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Res 76:6964\u20136974. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0258","journal-title":"Cancer Res"},{"key":"12982_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu X, Qin B, Zhang Y et al (2019) PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Mol Cell 74:1215\u20131226e4. https:\/\/doi.org\/10.1016\/j.molcel.2019.04.005","journal-title":"Mol Cell"},{"key":"12982_CR32","doi-asserted-by":"publisher","first-page":"e01039","DOI":"10.1016\/j.heliyon.2018.e01039","volume":"4","author":"X Wu","year":"2018","unstructured":"Wu X, Li Y, Liu X et al (2018) Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon 4:e01039. https:\/\/doi.org\/10.1016\/j.heliyon.2018.e01039","journal-title":"Heliyon"},{"key":"12982_CR33","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41556-020-0575-z","volume":"22","author":"J Hou","year":"2020","unstructured":"Hou J, Zhao R, Xia W et al (2020) PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol 22:1264\u20131275. https:\/\/doi.org\/10.1038\/s41556-020-0575-z","journal-title":"Nat Cell Biol"},{"key":"12982_CR34","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41418-020-00651-5","volume":"28","author":"W Du","year":"2021","unstructured":"Du W, Zhu J, Zeng Y et al (2021) KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6\/MerTK signaling pathway. Cell Death Differ 28:1284\u20131300. https:\/\/doi.org\/10.1038\/s41418-020-00651-5","journal-title":"Cell Death Differ"},{"key":"12982_CR35","doi-asserted-by":"publisher","first-page":"e0135528","DOI":"10.1371\/journal.pone.0135528","volume":"10","author":"Y Zhi","year":"2015","unstructured":"Zhi Y, Mou Z, Chen J et al (2015) B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. PLoS ONE 10:e0135528. https:\/\/doi.org\/10.1371\/journal.pone.0135528","journal-title":"PLoS ONE"},{"key":"12982_CR36","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-15-2665","volume":"22","author":"Y Lee","year":"2016","unstructured":"Lee Y, Shin JH, Longmire M et al (2016) CD44\u2009+\u2009Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. Clin Cancer Res Off J Am Assoc Cancer Res 22:3571\u20133581. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2665","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"12982_CR37","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/jca.19732","volume":"8","author":"M Nishino","year":"2017","unstructured":"Nishino M, Ozaki M, Hegab AE et al (2017) Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. J Cancer 8:1774\u20131785. https:\/\/doi.org\/10.7150\/jca.19732","journal-title":"J Cancer"},{"key":"12982_CR38","doi-asserted-by":"publisher","first-page":"9078209","DOI":"10.1155\/2019\/9078209","volume":"2019","author":"X Zhang","year":"2019","unstructured":"Zhang X, Li F, Zheng Y et al (2019) Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1\/Nanog In Vitro. Oxid Med Cell Longev 2019:9078209. https:\/\/doi.org\/10.1155\/2019\/9078209","journal-title":"Oxid Med Cell Longev"},{"key":"12982_CR39","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ijc.30834","volume":"141","author":"S Almozyan","year":"2017","unstructured":"Almozyan S, Colak D, Mansour F et al (2017) PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K\/AKT pathway activation. Int J Cancer 141:1402\u20131412. https:\/\/doi.org\/10.1002\/ijc.30834","journal-title":"Int J Cancer"},{"key":"12982_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J et al (2018) Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Front Oncol 8:386. https:\/\/doi.org\/10.3389\/fonc.2018.00386","journal-title":"Front Oncol"},{"key":"12982_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.02.022","volume":"450","author":"F Wei","year":"2019","unstructured":"Wei F, Zhang T, Deng S-C et al (2019) PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett 450:1\u201313. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.022","journal-title":"Cancer Lett"},{"key":"12982_CR42","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","volume":"1864","author":"XY Qiu","year":"2018","unstructured":"Qiu XY, Hu DX, Chen W-Q et al (2018) PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation. Biochim Biophys Acta Mol Basis Dis 1864:1754\u20131769. https:\/\/doi.org\/10.1016\/j.bbadis.2018.03.002","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"12982_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12032-015-0655-2","volume":"32","author":"Y Wang","year":"2015","unstructured":"Wang Y, Wang H, Zhao Q et al (2015) PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol 32:212. https:\/\/doi.org\/10.1007\/s12032-015-0655-2","journal-title":"Med Oncol"},{"key":"12982_CR44","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1159\/000480000","volume":"42","author":"L Chen","year":"2017","unstructured":"Chen L, Xiong Y, Li J et al (2017) PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 42:2267\u20132280. https:\/\/doi.org\/10.1159\/000480000","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"12982_CR45","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.2147\/CMAR.S257299","volume":"12","author":"P Cui","year":"2020","unstructured":"Cui P, Jing P, Liu X, Xu W (2020) Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma. Cancer Manag Res 12:5893\u20135902. https:\/\/doi.org\/10.2147\/CMAR.S257299","journal-title":"Cancer Manag Res"},{"key":"12982_CR46","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3727\/096504018X15446984186056","volume":"27","author":"Z Fei","year":"2019","unstructured":"Fei Z, Deng Z, Zhou L et al (2019) PD-L1 Induces Epithelial\u2013Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K\/AKT Pathway. Oncol Res 27:801\u2013807. https:\/\/doi.org\/10.3727\/096504018X15446984186056","journal-title":"Oncol Res"},{"key":"12982_CR47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12931-019-1137-4","volume":"20","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zeng Y, Liu T et al (2019) The canonical TGF-\u03b2\/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res 20:164. https:\/\/doi.org\/10.1186\/s12931-019-1137-4","journal-title":"Respir Res"},{"key":"12982_CR48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu W, Hua Y, Qiu H et al (2020) PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11:506. https:\/\/doi.org\/10.1038\/s41419-020-2701-z","journal-title":"Cell Death Dis"},{"key":"12982_CR49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B et al (2014) PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781\u2013790. https:\/\/doi.org\/10.1084\/jem.20131916","journal-title":"J Exp Med"},{"key":"12982_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-015-0421-2","volume":"14","author":"A Alsuliman","year":"2015","unstructured":"Alsuliman A, Colak D, Al-Harazi O et al (2015) Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 14:149. https:\/\/doi.org\/10.1186\/s12943-015-0421-2","journal-title":"Mol Cancer"},{"key":"12982_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","volume":"184","author":"X Wang","year":"2017","unstructured":"Wang X, Yang L, Huang F et al (2017) Inflammatory cytokines IL-17 and TNF-\u03b1 up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett 184:7\u201314. https:\/\/doi.org\/10.1016\/j.imlet.2017.02.006","journal-title":"Immunol Lett"},{"key":"12982_CR52","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH et al (2017) Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep 19:1189\u20131201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031","journal-title":"Cell Rep"},{"key":"12982_CR53","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ (2022) Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer 22:174\u2013189. https:\/\/doi.org\/10.1038\/s41568-021-00431-4","journal-title":"Nat Rev Cancer"},{"key":"12982_CR54","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"C-W Li","year":"2016","unstructured":"Li C-W, Lim S-O, Xia W et al (2016) Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632. https:\/\/doi.org\/10.1038\/ncomms12632","journal-title":"Nat Commun"},{"key":"12982_CR55","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X et al (2020) Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol 22:1064\u20131075. https:\/\/doi.org\/10.1038\/s41556-020-0562-4","journal-title":"Nat Cell Biol"},{"key":"12982_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol Off J Eur Soc Med Oncol 27:409\u2013416. https:\/\/doi.org\/10.1093\/annonc\/mdv615","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"12982_CR57","doi-asserted-by":"publisher","first-page":"2087204","DOI":"10.1155\/2016\/2087204","volume":"2016","author":"R Thapa","year":"2016","unstructured":"Thapa R, Wilson GD (2016) The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells Int 2016:2087204. https:\/\/doi.org\/10.1155\/2016\/2087204","journal-title":"Stem Cells Int"},{"key":"12982_CR58","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","volume":"80","author":"T Kong","year":"2020","unstructured":"Kong T, Ahn R, Yang K et al (2020) CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Res 80:444\u2013457. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1108","journal-title":"Cancer Res"},{"key":"12982_CR59","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"J-C Marine","year":"2020","unstructured":"Marine J-C, Dawson S-J, Dawson MA (2020) Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer 20:743\u2013756. https:\/\/doi.org\/10.1038\/s41568-020-00302-4","journal-title":"Nat Rev Cancer"},{"key":"12982_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69\u201384. https:\/\/doi.org\/10.1038\/s41580-018-0080-4","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12982_CR61","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C (2019) EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol 29:212\u2013226. https:\/\/doi.org\/10.1016\/j.tcb.2018.12.001","journal-title":"Trends Cell Biol"},{"key":"12982_CR62","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611\u2013629. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44","journal-title":"Nat Rev Clin Oncol"},{"key":"12982_CR63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4161\/15384101.2014.991572","volume":"14","author":"M Morita","year":"2015","unstructured":"Morita M, Gravel S-P, Hulea L et al (2015) mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle 14:473\u2013480. https:\/\/doi.org\/10.4161\/15384101.2014.991572","journal-title":"Cell Cycle"},{"key":"12982_CR64","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-10-4058","volume":"71","author":"P Gulhati","year":"2011","unstructured":"Gulhati P, Bowen KA, Liu J et al (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71:3246\u20133256. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4058","journal-title":"Cancer Res"},{"key":"12982_CR65","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12964-023-01225-x","volume":"21","author":"A Maharati","year":"2023","unstructured":"Maharati A, Moghbeli M (2023) PI3K\/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Commun Signal CCS 21:201. https:\/\/doi.org\/10.1186\/s12964-023-01225-x","journal-title":"Cell Commun Signal CCS"},{"key":"12982_CR66","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1038\/s41598-022-06430-1","volume":"12","author":"J Fierro","year":"2022","unstructured":"Fierro J, DiPasquale J, Perez J et al (2022) Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization. Sci Rep 12:2417. https:\/\/doi.org\/10.1038\/s41598-022-06430-1","journal-title":"Sci Rep"},{"key":"12982_CR67","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/cas.14690","volume":"112","author":"C Wang","year":"2021","unstructured":"Wang C, Weng M, Xia S et al (2021) Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. Cancer Sci 112:178\u2013193. https:\/\/doi.org\/10.1111\/cas.14690","journal-title":"Cancer Sci"},{"key":"12982_CR68","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ceb.2005.08.001","volume":"17","author":"MA Huber","year":"2005","unstructured":"Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548\u2013558. https:\/\/doi.org\/10.1016\/j.ceb.2005.08.001","journal-title":"Curr Opin Cell Biol"},{"key":"12982_CR69","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/onc.2013.118","volume":"33","author":"J Park","year":"2014","unstructured":"Park J, Schwarzbauer JE (2014) Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene 33:1649\u20131657. https:\/\/doi.org\/10.1038\/onc.2013.118","journal-title":"Oncogene"},{"key":"12982_CR70","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12672-025-02107-z","volume":"16","author":"Y Luo","year":"2025","unstructured":"Luo Y, Liu T, Pei J et al (2025) Emerging strategies and translational advancements of DDR1 in oncology. Discov Oncol 16:428. https:\/\/doi.org\/10.1007\/s12672-025-02107-z","journal-title":"Discov Oncol"},{"key":"12982_CR71","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S et al (2014) Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241. https:\/\/doi.org\/10.1038\/ncomms6241","journal-title":"Nat Commun"},{"key":"12982_CR72","doi-asserted-by":"publisher","first-page":"e1423170","DOI":"10.1080\/2162402X.2017.1423170","volume":"7","author":"A Asgarova","year":"2018","unstructured":"Asgarova A, Asgarov K, Godet Y et al (2018) PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 7:e1423170. https:\/\/doi.org\/10.1080\/2162402X.2017.1423170","journal-title":"Oncoimmunology"},{"key":"12982_CR73","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","volume":"25","author":"C Xu","year":"2014","unstructured":"Xu C, Fillmore CM, Koyama S et al (2014) Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25:590\u2013604. https:\/\/doi.org\/10.1016\/j.ccr.2014.03.033","journal-title":"Cancer Cell"},{"key":"12982_CR74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W, Li QK et al (2016) Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res 76:227\u2013238. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3362","journal-title":"Cancer Res"},{"key":"12982_CR75","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-017-1986-y","volume":"66","author":"R Okita","year":"2017","unstructured":"Okita R, Maeda A, Shimizu K et al (2017) PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother CII 66:865\u2013876. https:\/\/doi.org\/10.1007\/s00262-017-1986-y","journal-title":"Cancer Immunol Immunother CII"},{"key":"12982_CR76","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen N, Fang W, Zhan J et al (2015) Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 10:910\u2013923. https:\/\/doi.org\/10.1097\/JTO.0000000000000500","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"12982_CR77","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.resinv.2014.06.005","volume":"52","author":"G Toyokawa","year":"2014","unstructured":"Toyokawa G, Seto T (2014) Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Respir Investig 52:330\u2013338. https:\/\/doi.org\/10.1016\/j.resinv.2014.06.005","journal-title":"Respir Investig"},{"key":"12982_CR78","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","volume":"21","author":"K Ota","year":"2015","unstructured":"Ota K, Azuma K, Kawahara A et al (2015) Induction of PD-L1 Expression by the EML4\u2013ALK Oncoprotein and Downstream Signaling Pathways in Non\u2013Small Cell Lung Cancer. Clin Cancer Res 21:4014\u20134021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0016","journal-title":"Clin Cancer Res"},{"key":"12982_CR79","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.3892\/mmr.2018.8781","volume":"17","author":"L Zhang","year":"2018","unstructured":"Zhang L, Xu L-J, Zhu J et al (2018) ATM\u2013JAK\u2013PD\u2013L1 signaling pathway inhibition decreases EMT and metastasis of androgen\u2013independent prostate cancer. Mol Med Rep 17:7045\u20137054. https:\/\/doi.org\/10.3892\/mmr.2018.8781","journal-title":"Mol Med Rep"},{"key":"12982_CR80","doi-asserted-by":"publisher","first-page":"1359105","DOI":"10.3389\/fcell.2024.1359105","volume":"12","author":"LK Stevenson","year":"2024","unstructured":"Stevenson LK, Page AJ, Dowson M et al (2024) The DNA repair kinase ATM regulates CD13 expression and cell migration. Front Cell Dev Biol 12:1359105. https:\/\/doi.org\/10.3389\/fcell.2024.1359105","journal-title":"Front Cell Dev Biol"},{"key":"12982_CR81","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","volume":"49","author":"N Zhang","year":"2016","unstructured":"Zhang N, Zeng Y, Du W et al (2016) The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol 49:1360\u20131368. https:\/\/doi.org\/10.3892\/ijo.2016.3632","journal-title":"Int J Oncol"},{"key":"12982_CR82","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1038\/onc.2017.217","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang J, Jia Y, Zhao S et al (2017) BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR\/MAPK signaling pathways in non-small cell lung cancer. Oncogene 36:6235\u20136243. https:\/\/doi.org\/10.1038\/onc.2017.217","journal-title":"Oncogene"},{"key":"12982_CR83","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.7150\/ijms.84320","volume":"21","author":"X Liu","year":"2024","unstructured":"Liu X, Xu W, Li L et al (2024) Dual PI3K\/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer. Int J Med Sci 21:1814\u20131823. https:\/\/doi.org\/10.7150\/ijms.84320","journal-title":"Int J Med Sci"},{"key":"12982_CR84","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.jtocrr.2024.100666","volume":"5","author":"JW Neal","year":"2024","unstructured":"Neal JW, Santoro A, Gonzalez-Cao M et al (2024) Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clin Res Rep 5:100666. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100666","journal-title":"JTO Clin Res Rep"},{"key":"12982_CR85","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.eclinm.2023.102376","volume":"67","author":"D Li","year":"2024","unstructured":"Li D, Loriot Y, Burgoyne AM et al (2024) Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine 67:102376. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102376","journal-title":"EClinicalMedicine"},{"key":"12982_CR86","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","volume":"23","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, McGregor B, Maughan BL et al (2022) Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol 23:899\u2013909. https:\/\/doi.org\/10.1016\/S1470-2045(22)00278-9","journal-title":"Lancet Oncol"},{"key":"12982_CR87","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO-24-01675","volume":"43","author":"SK Pal","year":"2025","unstructured":"Pal SK, Loriot Y, Necchi A et al (2025) COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. J Clin Oncol Off J Am Soc Clin Oncol 43:1650\u20131662. https:\/\/doi.org\/10.1200\/JCO-24-01675","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12982_CR88","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-25-4364","volume":"32","author":"C Tiu","year":"2026","unstructured":"Tiu C, Yau W, Silva D et al (2026) Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K\/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 32:3179\u20133194. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-4364","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"12982_CR89","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6:425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"key":"12982_CR90","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","volume":"23","author":"Y Xia","year":"2025","unstructured":"Xia Y, Huang C, Zhong M et al (2025) Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion. Cell Commun Signal CCS 23:46. https:\/\/doi.org\/10.1186\/s12964-025-02033-1","journal-title":"Cell Commun Signal CCS"},{"key":"12982_CR91","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","volume":"36","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Penkov K, Uemura H et al (2025) Avelumab\u2009+\u2009axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol Off J Eur Soc Med Oncol 36:387\u2013392. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.008","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"12982_CR92","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.esmoop.2021.100101","volume":"6","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Larkin J, Pal S et al (2021) Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open 6:100101. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100101","journal-title":"ESMO Open"},{"key":"12982_CR93","doi-asserted-by":"publisher","first-page":"104909","DOI":"10.1016\/j.yexmp.2024.104909","volume":"138","author":"T \u010cugura","year":"2024","unstructured":"\u010cugura T, Bo\u0161tjan\u010di\u010d E, Uhan S et al (2024) Epithelial-mesenchymal transition associated markers in sarcomatoid transformation of clear cell renal cell carcinoma. Exp Mol Pathol 138:104909. https:\/\/doi.org\/10.1016\/j.yexmp.2024.104909","journal-title":"Exp Mol Pathol"},{"key":"12982_CR94","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","volume":"17","author":"KA Blum","year":"2020","unstructured":"Blum KA, Gupta S, Tickoo SK et al (2020) Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 17:659\u2013678. https:\/\/doi.org\/10.1038\/s41585-020-00382-9","journal-title":"Nat Rev Urol"},{"key":"12982_CR95","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P et al (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402:185\u2013195. https:\/\/doi.org\/10.1016\/S0140-6736(23)00922-4","journal-title":"Lancet"},{"key":"12982_CR96","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","volume":"40","author":"J Fu","year":"2021","unstructured":"Fu J, Su X, Li Z et al (2021) HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 40:4625\u20134651. https:\/\/doi.org\/10.1038\/s41388-021-01863-w","journal-title":"Oncogene"},{"key":"12982_CR97","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1200\/JCO-25-01840","volume":"44","author":"F Jackson-Spence","year":"2026","unstructured":"Jackson-Spence F, Larkin J, Patel P et al (2026) CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. J Clin Oncol Off J Am Soc Clin Oncol 44:1076\u20131082. https:\/\/doi.org\/10.1200\/JCO-25-01840","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"12982_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","volume":"42","author":"Q Wu","year":"2021","unstructured":"Wu Q, Jiang L, Li S-C et al (2021) Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway. Acta Pharmacol Sin 42:1\u20139. https:\/\/doi.org\/10.1038\/s41401-020-0366-x","journal-title":"Acta Pharmacol Sin"},{"key":"12982_CR99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu J-M, Yang W-H, Hung M-C (2022) Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol 19:287\u2013305. https:\/\/doi.org\/10.1038\/s41571-022-00601-9","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12982-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:55Z","timestamp":1792796635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12982-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12982"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12982-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This narrative review did not involve new research with human participants or animals.","order":2,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1793"}}